Randomized Double-blind Trial to Study the Benefit of Colchicine in Patients With Acutely Decompensated Heart Failure
Status:
Recruiting
Trial end date:
2023-05-16
Target enrollment:
Participant gender:
Summary
Heart failure (HF) is a chronic disease associated with multiple acute decompensations, which
are the main cause of hospital admission above 65 years and two thirds of the high costs
associated with the disease. Furthermore, in the patient they reflect a phase of clinical
instability, with a higher risk of early readmission (20-30% at 30 days) and higher mortality
(10-15% at 30 days and 30-40% at 1year).
However, the investigators do not have treatments specifically aimed at this unstable phase,
known as acute or decompensated (HF). It is known that, in this acute and unstable state,
there is an increase in inflammatory parameters. Indeed, our group has recently demonstrated
the relevance of the interleukin-1 axis, in particular IL-1beta and sST2 concentrations
identified a worse prognosis regardless of HF phenotype. Colchicine, a widely available drug,
has proven to be a powerful cardiovascular anti-inflammatory, acting on inflammasome and
therefore inhibiting the production of IL1-beta.The study hypothesis is that colchicine
administered early during the acute phase can promote stability in terms of biomarkers of
cardiac function and new decompensations. For this it is designed a randomized, double-blind
clinical study with two arms (colchicine 0.5 mg vs. placebo) initiated within the first 24
hours of hospitalisation and administered for 60 days, in patients with acute decompensated
HF with either reduced or preserved LV ejection fraction.
Phase:
Phase 3
Details
Lead Sponsor:
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia